Ligand Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
14
Price Target
$158.50
Consensus
Outperform
Upside
121.83%
Analysts
2
Stock Rating
14
Upside
121.83%
Analysts
2
Price Target
$158.50

Ligand Pharmaceuticals Stock Forecast and Price Target

Ligand Pharmaceuticals has an average price target of $158.50 recently offered by two notable experts for 2023, which would represent a potential upside of approximately 121.83% from the last closing price in February, 2023 if reached. This potential increase is based on a high estimate of $310.00 and a low estimate of $130.00. Even if you are not interested in LGND stock, you should still be aware of its competitors.

$158.50

121.83% Upside

Outperform
Outperform

Ligand Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Price for Ligand Pharmaceuticals has grown by 107.77%, going from $70.95 to $147.40. According to 0 analysts, Ligand Pharmaceuticals's Fair Value will fall by 30.12% in the next year, reaching $103.01. Professionals believe that By 2030, Ligand Pharmaceuticals's Fair Value will fall to $111.44 – a 24.40% decrease from its current value.

2022 Fair Value Forecast
$103.01
2023 Fair Value Forecast
$96.79
2024 Fair Value Forecast
$103.37
2025 Fair Value Forecast
$118.24
2026 Fair Value Forecast
$113.31
2027 Fair Value Forecast
$107.80
2028 Fair Value Forecast
$106.68
2029 Fair Value Forecast
$110.42
2030 Fair Value Forecast
$111.44

Ligand Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Revenue for Ligand Pharmaceuticals has grown by 130.40%, going from $120.28M to $277.13M. According to 0 analysts, Ligand Pharmaceuticals's Revenue will fall by 33.65% in the next year, reaching $183.88M. Professionals believe that By 2030, Ligand Pharmaceuticals's Revenue will fall to $203.34M – a 26.62% decrease from its current value.

2022 Rev Forecast
$0.18B
2023 Rev Forecast
$0.17B
2024 Rev Forecast
$0.19B
2025 Rev Forecast
$0.22B
2026 Rev Forecast
$0.21B
2027 Rev Forecast
$0.20B
2028 Rev Forecast
$0.19B
2029 Rev Forecast
$0.20B
2030 Rev Forecast
$0.20B

Ligand Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

Ligand Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Ligand Pharmaceuticals's Free Cash Flow has grown, increasing from $-31.89M to $70.04M – an increase of 319.63%. For the following year, the 0 analysts predict that Ligand Pharmaceuticals's Free Cash Flow will drop by 73.49%, reaching $18.57M. In 2030, the professionals' prediction is that LGND's Free Cash Flow will decrease by 26.65%, reaching $51.37M.

2022 FCF Forecast
$0.02B
2023 FCF Forecast
$0.02B
2024 FCF Forecast
$0.04B
2025 FCF Forecast
$0.07B
2026 FCF Forecast
$0.05B
2027 FCF Forecast
$0.04B
2028 FCF Forecast
$0.04B
2029 FCF Forecast
$0.05B
2030 FCF Forecast
$0.05B

Ligand Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Ligand Pharmaceuticals's Net Income has decreased by 90.92%, going from $629.30M to $57.14M. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $4.04B – an increase of 6978.79%. By 2030, professionals predict that Ligand Pharmaceuticals's Net Income will decrease by 1420771647.42%, to $-811.83T.

2022 NI Forecast
$4.04B
2023 NI Forecast
$286.41B
2024 NI Forecast
$-2300856018.34
2025 NI Forecast
$-97026714817.37
2026 NI Forecast
$-4091910878216.70
2027 NI Forecast
$-1.7258138797887E+14
2028 NI Forecast
$-4090178895099.20
2029 NI Forecast
$-57591763932445.00
2030 NI Forecast
$-8.1182886219546E+14

Ligand Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

Ligand Pharmaceuticals's EBITDA has increased by 142.67% In the last two years, going from $38.01M to $92.24M. In the following year, the 0 analysts surveyed believe that Ligand Pharmaceuticals's EBITDA will decrease by 36.44%, reaching $58.63M. According to professionals, by 2030, Ligand Pharmaceuticals's EBITDA will have decreased by 28.30%, falling down to $66.14M.

2022 EBITDA Forecast
$0.06B
2023 EBITDA Forecast
$0.06B
2024 EBITDA Forecast
$0.06B
2025 EBITDA Forecast
$0.07B
2026 EBITDA Forecast
$0.07B
2027 EBITDA Forecast
$0.06B
2028 EBITDA Forecast
$0.06B
2029 EBITDA Forecast
$0.07B
2030 EBITDA Forecast
$0.07B

Ligand Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Ligand Pharmaceuticals's EBIT has grown, increasing from $-5.72M to $41.30M – a growth of 822.03%. The next year, 0 experts forecast that Ligand Pharmaceuticals's EBIT will decrease by 58.97%, reaching $16.94M. In 2030, professionals predict that Ligand Pharmaceuticals's EBIT will decrease by 35.60%, reaching $26.60M.

2022 EBIT Forecast
$0.02B
2023 EBIT Forecast
$0.02B
2024 EBIT Forecast
$0.02B
2025 EBIT Forecast
$0.03B
2026 EBIT Forecast
$0.03B
2027 EBIT Forecast
$0.02B
2028 EBIT Forecast
$0.02B
2029 EBIT Forecast
$0.03B
2030 EBIT Forecast
$0.03B

Ligand Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, EPS for Ligand Pharmaceuticals has grown by 107.77%, going from $3.09 to $6.42. According to 0 analysts, Ligand Pharmaceuticals's EPS will fall by 30.12% in the next year, reaching $4.49. Professionals believe that By 2030, Ligand Pharmaceuticals's EPS will fall to $4.85 – a 24.40% decrease from its current value.

2022 EPS Forecast
$4.49
2023 EPS Forecast
$4.22
2024 EPS Forecast
$4.50
2025 EPS Forecast
$5.15
2026 EPS Forecast
$4.93
2027 EPS Forecast
$4.69
2028 EPS Forecast
$4.65
2029 EPS Forecast
$4.81
2030 EPS Forecast
$4.85